Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer.
CyberKnife
HRQoL (health-related quality of life)
SBRT (stereotactic body radiation therapy)
financial toxicity
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
01
2022
accepted:
28
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
In patients with localized prostate cancer, 5-fraction, stereotactic body radiation therapy (SBRT) has been found to offer comparable oncologic outcomes and potential for improved treatment compliance compared to conventional, 40-plus fraction radiation therapy (RT). Recent studies of oncologic patient experiences have highlighted both the impact of therapy-associated financial toxicity (FT) on treatment adherence and health-related quality of life (HRQOL). A cross-sectional assessment of FT after SBRT was performed using the 12-item COST questionnaire. The total questionnaire score (range 0-44) was used to evaluate the FT grade (0-3), with a higher COST value representing lower grade. The patient zip code was used to approximate the distance from the index hospital. Univariate and multivariate analyses of the average COST score (0-4) are performed. The response rate was 57.5% (332 of 575 consented patients) with 90.7%, 8.2%, and 1.1% experiencing grade 0, 1, and 2 FT, respectively, with no grade 3. Unemployment or disability, non-white race, low income, and concurrent hormonal therapy were associated with a statistically significant worse FT (lower COST value) on univariate and multivariate analyses (p < 0.05). Education level and insurance status significant were evaluated on univariate analysis only. There was a non-statistically significant difference in age, marital status, time since treatment, and distance from the index hospital. SBRT was associated with low FT. However, statistically significant socioeconomic disparities in FT remain despite ultra-hypofractionated treatment.
Identifiants
pubmed: 35402242
doi: 10.3389/fonc.2022.852844
pmc: PMC8990911
doi:
Types de publication
Journal Article
Langues
eng
Pagination
852844Informations de copyright
Copyright © 2022 Sholklapper, Creswell, Payne, Markel, Pepin, Carrasquilla, Zwart, Danner, Ayoob, Yung, Collins, Kumar, Aghdam, Suy, Hankins, Kowalczyk and Collins.
Déclaration de conflit d'intérêts
SC and BC serve as clinical consultants at Accuray Inc. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Prostate. 2010 Aug;70(11):1255-64
pubmed: 20658653
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Support Care Cancer. 2020 Apr;28(4):1703-1715
pubmed: 31292755
Eur Urol Oncol. 2021 Jun;4(3):396-404
pubmed: 33820747
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):815-826
pubmed: 32234552
J Geriatr Oncol. 2021 Mar;12(2):305-311
pubmed: 32739353
Cancer. 2017 Feb 1;123(3):476-484
pubmed: 27716900
Nat Rev Urol. 2020 Jan;17(1):28-40
pubmed: 31792431
J Urol. 2021 Mar;205(3):761-768
pubmed: 33252300
J Urol. 2018 Jul;200(1):43-45
pubmed: 29113839
J Oncol Pract. 2018 Oct 24;:JOP1800120
pubmed: 30355027
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Radiat Oncol. 2013 Mar 13;8:58
pubmed: 23497695
Front Oncol. 2021 Feb 25;10:616286
pubmed: 33718117
Am J Med. 2018 Oct;131(10):1187-1199.e5
pubmed: 29906429
J Med Internet Res. 2005 Jul 01;7(3):e29
pubmed: 15998620
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33
pubmed: 14697417
Pract Radiat Oncol. 2020 Sep - Oct;10(5):e322-e329
pubmed: 31634632